25 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 25 of 25 clinical reviews.
Does Prolia (denosumab) affect appetite or cravings? A clinician-level review of the FREEDOM trial data, FDA adverse-event records, RANK/RANKL biology, and practical management steps for patients on denosumab.
A clinician-level review of denosumab (Prolia) use in patients with autoimmune disease: mechanism, immunological risks, drug interactions, monitoring protocols, and guidance from FREEDOM and post-marketing data.
A physician-reviewed, evidence-based guide to how denosumab (Prolia) affects bone mineral density, fracture risk, and long-term skeletal outcomes. Includes FREEDOM trial data, dosing, discontinuation risks, and clinical decision frameworks.
A board-reviewed, primary-literature analysis of the cancer risk signals associated with denosumab (Prolia), covering FREEDOM trial data, FDA labeling updates, post-marketing surveillance, and clinical decision-making guidance for prescribers.
A physician-reviewed, evidence-based analysis of denosumab's long-term cardiovascular effects, covering atrial fibrillation, hypocalcemia-related arrhythmia, MACE data, and what clinicians need to monitor in practice.
A physician-reviewed deep-dive into denosumab (Prolia) and cognition: RANKL biology, FREEDOM trial data, pharmacovigilance signals, and clinical decision-making for patients concerned about brain fog or cognitive decline.
A physician-reviewed comparison of compounded denosumab versus branded Prolia, covering efficacy data, safety profiles, regulatory status, cost, and clinical decision-making for osteoporosis treatment.
A physician-level review of denosumab (Prolia) evidence graded by GRADE methodology, covering fracture reduction, bone density, and safety across key RCTs including FREEDOM, FREEDOM Extension, and current AACE/Endocrine Society guidelines.
A clinical deep-dive into denosumab-associated dermatologic adverse effects, including eczema, cellulitis, alopecia, and rash, with primary-literature citations and practical management guidance.
A comprehensive, physician-reviewed guide to how denosumab (Prolia) affects liver function, including hepatotoxicity risk, lab monitoring, mechanism of action, and clinical trial data from FREEDOM and post-marketing surveillance.
A clinician-level review of denosumab (Prolia) and its effects on mental health, mood, depression, and neuropsychiatric symptoms. Includes trial data, mechanism analysis, and prescribing guidance.
A clinician-level review of how denosumab affects bone metabolism, RANKL-OPG signaling, energy expenditure, and body composition, with primary-literature citations from FREEDOM and beyond.
A physician-level review of denosumab (Prolia) dosing, the absence of validated microdosing protocols, fracture-risk rebound data, and what clinicians should do instead.
An MD/PharmD-level review of how denosumab (Prolia) affects skeletal muscle, what the FREEDOM trial and downstream research revealed, and evidence-based strategies to preserve or build muscle during RANK-L inhibition therapy.
MD/PharmD-level guide to diagnosing and managing BMD plateau and non-response on denosumab (Prolia): secondary causes, lab workup, dose timing, combination therapy, and when to switch agents.
A clinician-level guide to using denosumab (Prolia) after bariatric surgery, covering fracture risk, calcium repletion, FREEDOM trial data, dosing, and monitoring protocols.
A comprehensive clinical guide to the denosumab pre-surgery hold window, covering fracture rebound risk, optimal timing, bridging strategies, and evidence-based protocols for perioperative management of Prolia patients.
Stopping Prolia (denosumab) triggers rapid, severe bone loss and vertebral fracture risk within 7 to 12 months. This MD-level guide covers the rebound mechanism, fracture data, transition protocols, and clinical decision frameworks.
A clinician-level review of denosumab (Prolia) and kidney function: evidence from FREEDOM and post-marketing data on hypocalcemia risk, CKD dosing, and who benefits most.
A clinical guide to denosumab (Prolia) seasonal administration timing, rebound fracture risk, dosing intervals, and practical scheduling strategies for clinicians and patients.
A clinician-level review of denosumab's (Prolia) effects on sexual function, covering hormonal pathways, trial data from FREEDOM and related studies, and practical guidance for patients and prescribers.
A clinician-level review of how denosumab (Prolia) may affect sleep architecture, RANKL signaling in the CNS, bone-pain relief and its downstream effects on sleep quality, and what patients and prescribers need to know.
MD/PharmD-level guidance on managing denosumab injection timing during travel, timezone shifts, and international trips. Covers the 6-month dosing window, cold-chain requirements, and what to do if your Prolia shot is delayed.
A clinician-level guide to safely restarting denosumab (Prolia) after acute illness, covering the rebound fracture risk, timing windows, bridging strategies, and current guideline recommendations.
A week-by-week clinical guide to the first month on Prolia (denosumab): injection-site reactions, bone-marker changes, calcium monitoring, and what your first 30 days actually look like based on FREEDOM and post-marketing data.